A Composite Assay for HER2-positive Early-stage Breast Cancer Management
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this observational study is to assess the prognostic value of a genomic classifier (S18) and its refined version (S\*) in women with early-stage HER2-positive breast cancer. The study aims to determine whether these tools can predict event-free (EFS) and disease-free survival (DFS) in patients treated with neoadjuvant and/or adjuvant trastuzumab-based therapies.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjentki w wieku 18 lat lub starsze.
- •Rak piersi we wczesnym stadium (I-III stopnia), który można operować.
- •Rak piersi HER2-dodatni, potwierdzony odpowiednimi badaniami.
- •Pacjentki leczone lub leczone wcześniej lekami zawierającymi trastuzumab (czasem z pertuzumabem).
- •Wyrażenie pisemnej zgody na udział w badaniu.
✗ Disqualifies
- •Pacjentki, u których od operacji minęło mniej niż 3 lata.
- •Pacjentki, u których wcześniej zdiagnozowano innego rodzaju raka.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- January 8, 2025
- Sex
- No restrictions
Locations (2)
Ospedale Di Summa-Perrino
Brindisi, Italy
Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
Naples, Italy
Trial contact
Serena Di Cosimo, MD, PhD
Paolo Verderio, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.